Seiji Miwatashi

Summary

Affiliation: Pharmaceutical Research Division
Country: Japan

Publications

  1. ncbi request reprint Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as p38 MAP kinase inhibitors
    Seiji Miwatashi
    Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, Osaka
    Chem Pharm Bull (Tokyo) 53:410-8. 2005
  2. ncbi request reprint Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent
    Seiji Miwatashi
    Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 17 85 Jusohonmachi 2 Chome, Yodogawa ku, Osaka, 532 8686, Japan
    J Med Chem 48:5966-79. 2005
  3. ncbi request reprint Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as selective adenosine A3 antagonists
    Seiji Miwatashi
    Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, Osaka, Japan
    Chem Pharm Bull (Tokyo) 56:1126-37. 2008
  4. ncbi request reprint Novel acetylcholinesterase inhibitor as increasing agent on rhythmic bladder contractions: SAR of 8-{3-[1-(3-fluorobenzyl)piperidin-4-yl]propanoyl}-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (TAK-802) and related compounds
    Yuji Ishichi
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 2 17 85, Jusohonmachi, Yodogawa ku, Osaka 532 8686, Japan
    Bioorg Med Chem 13:1901-11. 2005

Collaborators

Detail Information

Publications4

  1. ncbi request reprint Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as p38 MAP kinase inhibitors
    Seiji Miwatashi
    Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, Osaka
    Chem Pharm Bull (Tokyo) 53:410-8. 2005
    ..Further elucidation of this class of compounds may provide novel anti-inflammatory agents, such as anti-rheumatoid arthritis drugs...
  2. ncbi request reprint Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent
    Seiji Miwatashi
    Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 17 85 Jusohonmachi 2 Chome, Yodogawa ku, Osaka, 532 8686, Japan
    J Med Chem 48:5966-79. 2005
    ..Compound 8h was selected as a clinical candidate and is now under clinical investigation for the treatment of RA...
  3. ncbi request reprint Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as selective adenosine A3 antagonists
    Seiji Miwatashi
    Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, Osaka, Japan
    Chem Pharm Bull (Tokyo) 56:1126-37. 2008
    ..Further evaluation of this class of compounds may afford a novel anti-inflammatory agent such as an anti-asthmatic drug...
  4. ncbi request reprint Novel acetylcholinesterase inhibitor as increasing agent on rhythmic bladder contractions: SAR of 8-{3-[1-(3-fluorobenzyl)piperidin-4-yl]propanoyl}-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (TAK-802) and related compounds
    Yuji Ishichi
    Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 2 17 85, Jusohonmachi, Yodogawa ku, Osaka 532 8686, Japan
    Bioorg Med Chem 13:1901-11. 2005
    ....